预约演示

Astellas continues gene therapy push with $50M for stake in Taysha, options on 2 CNS assets

2022-10-24

合作基因疗法并购

A newly announced agreement gives Astellas certain rights when it comes to signing off on any potential change of control of Taysha Gene Therapies.

Astellas will sink $50 million intAstellas Gene Therapies in exchange for a 15% stake in the biotech and the option to licensTaysha Gene Therapiesidates for two rare neurological disorders.

Astellasadeno-associated virus (AAV)Taysha Gene Therapiesestion are TSHA-102, the only gene therapy in the clinic for Rett syndrome, and TSHA-120, which is in phase 1neurological disordersnal neuropathy.

Astellas touted the deal as the continuation of a gene therapy stratTSHA-102 saw the Japanese Big Pharma acquire AudenRett syndromellion TSHA-120ry 2020 and open a gene therapy manufacturing facility in North Carolina four months ago.

Astellasthe candidates covered by the deal are AAV9 gene replacement therapies. TSHA-102 utilizes Taysha’s miRNA-Audentesve auto-regulatory element (miRARE) platform to regulate transgene expression on a cell-by-cell basis, while TSHA-120 delivers the gene gigaxonin.

“Taysha is an industry leader in CNS gene therapies and this partnership fits stTSHA-102lly with our long-term vision of expanding Astellas’ gene therapy capabilities, allowing the company to impact the lives of a broader range ofTSHA-120s with urgent unmet medical needs,” Astellas Chief Strategy Officer Naoki Okamura said in a postmarket release Monday.

TTayshaeement also gives Astellas certain rights when it comes to signing off on any potential change of control of Taysha. In the Astellas, Astellas will take up an observer seat on Taysha’s board of directors, which the companies said would enable the biotech to leverage Astellas’ clinical and commercial expertise.

Taysha has one other candAstellas the clinic that isn't covered by the Astellas deal—a therapy called TSHA-118 in phTaysha2 development for aAstellasted nervous system disorder calledTayshadisease.Astellas

For Astellas, the route into gene therapy offered by the Audentes acquisition hasn’t always gone smootTSHA-118ns to file AT132 for approval in inherited nervous system disorder knockedCLN1 diseaseby patient deaths, while the Big Pharma decided to terminate work on a clinical-phase therapy called AT702 for Duchenne muscular dystrophy as well as two earlier-stage candidates for the condition after taking a look at a preclinical study.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构

Astellas